Pancreatic Cancer ARTNet Center
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11421828 · Data updated 2026-11-12
A national-center effort aims to understand why pancreatic cancer resist chemotherapy and to develop better treatment strategies for patients with this cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,266,014 |
| NIH project number | 5U54CA274329-05 |
| Project ID | NIH-11421828 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic cancer who have limited response to current chemotherapy and are candidates for new therapeutic approaches.
✕Less likely to help
Patients not eligible for future trials or whose cancer biology does not align with the proposed mechanisms may not benefit.
What this research studies
This project brings together experts to study how cancer cells and their surrounding tissue respond to chemotherapy and to identify new combination therapies. It focuses on signaling and metabolic changes that drive resistance, and on coordinating translation of findings into better patient care. By integrating leadership from national networks and institutions, the center plans to test novel ideas that could improve long-term responses for people with pancreatic cancer. The work involves collaboration, data sharing, and preclinical to translational research designed with patient benefit in mind.
Why it matters
Potential benefit: If successful, the center could lead to therapies that overcome resistance and improve survival for pancreatic cancer patients.
How similar studies have gone: Previous work shows that targeting metabolic and signaling pathways can enhance chemotherapy effectiveness in pancreatic cancer, supporting further exploration.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Singh, Pankaj Kumar — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Singh, Pankaj Kumar
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.